西达本胺片 | China Drugs ListChidamide tablets | China Drugs List
本页为公开参考信息，不构成医疗建议、处方或药品供应要约。请向持证专业人士确认当前批准情况、可获得性及适用性。
- 商品名
- 爱谱沙Epidaza
- 企业
- 深圳微芯生物Shenzhen Chipscreen Biosciences
- 药品类型
- 化学药Chemical medicine
- 治疗领域
- 肿瘤科Oncology
- 公开来源记录的适应症
- ①既往至少接受过一次全身化疗的复发或难治性外周T细胞淋巴瘤（PTCL）；②联合芳香化酶抑制剂，治疗HR阳性、HER2阴性、绝经后且内分泌治疗后复发或进展的局部晚期或转移性乳腺癌；③联合R-CHOP方案（利妥昔单抗、环磷酰胺、阿霉素、长春新碱和强的松），治疗既往未经治疗、MYC和BCL2表达阳性的弥漫性大B细胞淋巴瘤（DLBCL）。其中说明书列明PTCL及DLBCL为附条件批准范围。(1) Relapsed or refractory peripheral T-cell lymphoma (PTCL) after at least one previous course of systemic chemotherapy. (2) With an aromatase inhibitor for postmenopausal patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer that has relapsed or progressed after endocrine therapy. (3) With R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) for previously untreated diffuse large B-cell lymphoma (DLBCL) expressing both MYC and BCL2. The label identifies the PTCL and DLBCL indications as conditionally approved.
- 适应症来源与口径
- 2024-04-24
- 说明书信息局限
- 已取得完整官方药品说明书。 中国大陆说明书。Complete official prescribing information obtained. Mainland China label.
- 中国可获得性状态
- 已核实中国历史批准记录；尚未逐项核查每个产品目前是否持续上市销售。Historical Chinese approval verified; current continuous market availability has not been checked for every product.
- 海外状态
- 日本: 已取得当地获批／上市公告及官方价格来源。每条价格记录注明适应症与日期；未全面核查其他市场。Japan: local approval / launch announcements and official price sources obtained. Indications and dates are specified in each price record; other markets not exhaustively reviewed.
- 医保分类
- 已纳入国家医保（乙类）Included in national insurance (Category B)
- 医保版本
- 2025版；2026年1月1日起执行2025 edition; effective 1 January 2026
- 医保限制
- 限：1.既往至少接受过一次全身化疗的复发或难治的外周T细胞淋巴瘤(PTCL)患者；2.联合R-CHOP(利妥昔单抗、环磷酰胺、阿霉素、长春新碱和强的松)用于MYC和BCL2表达阳性的既往未经治疗的弥漫大B细胞淋巴瘤(DLBCL)患者。Restricted to: (1) relapsed or refractory PTCL after at least one previous course of systemic chemotherapy; (2) use with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) for previously untreated DLBCL expressing both MYC and BCL2.
- 医保核查说明
- 按成分／剂型名称精确或标准化匹配。报销仍取决于剂型及目录所列支付限制。Matched by exact or normalized ingredient/formulation name. Reimbursement still depends on the dosage form and listed payment restrictions.